Upregulation of Key Molecules for Targeted Imaging and Therapy-Reference-Cited by-同舟云学术

Upregulation of Key Molecules for Targeted Imaging and Therapy

Published:2016-06-30 Issue:11 Volume:57 Page:1805-1810
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Taelman Vincent F.,Radojewski Piotr,Marincek Nicolas,Ben-Shlomo Anat,Grotzky Andrea,Olariu Cristina I.,Perren Aurel,Stettler Christoph,Krause Thomas,Meier Lorenz P.,Cescato Renzo,Walter Martin A.

Publisher

Society of Nuclear Medicine

Subject

Radiology Nuclear Medicine and imaging

Reference32 articles.

1. Lanreotide in metastatic enteropancreatic neuroendocrine tumors;Caplin;N Engl J Med.,2014

2. Yttrium-90 DOTATOC: first clinical results

3. Somatostatin Receptor–Targeted Radiopeptide Therapy with 90Y-DOTATOC and 177Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Trial

4. Molecular Imaging Radiotherapy: Theranostics for Personalized Patient Management of Neuroendocrine Tumors (NETs)

5. Staging of neuroendocrine tumours: comparison of [68Ga]DOTATOC multiphase PET/CT and whole-body MRI

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gastroenteropancreatic neuroendocrine tumors: Epigenetic landscape and clinical implications;Current Problems in Cancer;2024-10

2. May the Nuclear Medicine be with you! Neuroendocrine tumours and the return of nuclear medicine;European Journal of Nuclear Medicine and Molecular Imaging;2024-08-19

3. Das Deutsche Zentrum für Psychische Gesundheit;Der Nervenarzt;2024-03-15

4. Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments;Theranostics;2024

5. Diagnosis and Management of Aggressive/Refractory Growth Hormone‐Secreting Pituitary Neuroendocrine Tumors;International Journal of Endocrinology;2024-01